Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김희영 | * |
dc.contributor.author | 김휘영 | * |
dc.date.accessioned | 2018-11-21T16:30:36Z | - |
dc.date.available | 2018-11-21T16:30:36Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 1471-2407 | * |
dc.identifier.other | OAK-22247 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246800 | - |
dc.description.abstract | Background: Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based model for predicting sorafenib response and overall survival (OS). Methods: This prospective cohort study included 124 consecutive HCC patients (44 with disease control, 80 with progression) with Child-Pugh class A liver function, who received sorafenib. Potential serum biomarkers (namely, hepatocyte growth factor [HGF], fibroblast growth factor [FGF], vascular endothelial growth factor receptor-1, CD117, and angiopoietin-2) were tested. After identifying independent predictors of tumor response, a risk scoring system for predicting OS was developed and 3-fold internal validation was conducted. Results: A risk scoring system was developed with six covariates: etiology, platelet count, Barcelona Clinic Liver Cancer stage, protein induced by vitamin K absence-II, HGF, and FGF. When patients were stratified into low-risk (score ≤ 5), intermediate-risk (score 6), and high-risk (score ≥ 7) groups, the model provided good discriminant functions on tumor response (concordance [c]-index, 0.884) and 12-month survival (area under the curve [AUC], 0.825). The median OS was 19.0, 11.2, and 6.1 months in the low-, intermediate-, and high-risk group, respectively (P < 0.001). In internal validation, the model maintained good discriminant functions on tumor response (c-index, 0.825) and 12-month survival (AUC, 0.803), and good calibration functions (all P > 0.05 between expected and observed values). Conclusions: This new model including serum FGF and HGF showed good performance in predicting the response to sorafenib and survival in patients with advanced HCC. © 2018 The Author(s). | * |
dc.description.sponsorship | Ewha Womans University | * |
dc.language | English | * |
dc.publisher | BioMed Central Ltd. | * |
dc.subject | Biomarker | * |
dc.subject | Hepatocellular carcinoma | * |
dc.subject | Prediction | * |
dc.subject | Response | * |
dc.subject | Sorafenib | * |
dc.title | Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: A prospective cohort study | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 18 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | BMC Cancer | * |
dc.identifier.doi | 10.1186/s12885-018-4211-2 | * |
dc.identifier.wosid | WOS:000428275900006 | * |
dc.identifier.scopusid | 2-s2.0-85044181218 | * |
dc.author.google | Kim H.Y. | * |
dc.author.google | Lee D.H. | * |
dc.author.google | Lee J.-H. | * |
dc.author.google | Cho Y.Y. | * |
dc.author.google | Cho E.J. | * |
dc.author.google | Yu S.J. | * |
dc.author.google | Kim Y.J. | * |
dc.author.google | Yoon J.-H. | * |
dc.contributor.scopusid | 김휘영(56493773500) | * |
dc.date.modifydate | 20240429140130 | * |